파라오 슬롯 sets sights on becoming a global CDMO leader, leveraging cutting-edge R&D capabilities and expanding into high-value services.
“In 2031, we aim to achieve 0 million in sales from contract development (CDO) and clinical trial services (CRO), and .4 billion from contract manufacturing (CMO), totaling an expected revenue of .1 billion.”
Jung-jin Seo, Chairman of the 파라오 슬롯 Group, announced these ambitious goals during an online press conference on December 17th, introducing the newly established 파라오 슬롯 BioSolutions (hereafter BioSolutions), a 100%-owned subsidiary and dedicated CDMO (Contract Development and Manufacturing Organization). The event showcased BioSolutions’ global strategy, R&D capabilities, and roadmap.
Hyuk-Jae Lee, Senior Vice President at 파라오 슬롯 with extensive experience in regulatory approvals, clinical trials, and manufacturing, was appointed CEO of BioSolutions. The new company offers comprehensive drug development services, including candidate identification, cell line and process development, clinical trials, regulatory documentation, and commercial manufacturing.
Chairman Seo explained, “BioSolutions was launched as a wholly-owned subsidiary of 파라오 슬롯 to provide integrated services from development to manufacturing. We decided on its establishment in September and officially founded it on December 17th to fully commit to this market.”
He added, “In the mid-2000s, 파라오 슬롯 was the second-largest CMO company globally after Lonza. Although we still operate CMO businesses, increasing demand from small biotech firms for integrated services prompted us to create this dedicated entity.”
BioSolutions plans to begin constructing manufacturing facilities in the first half of 2025. However, CDO and CRO services will start earlier, leveraging 파라오 슬롯’s R&D expertise in antibody platforms, cell and gene therapies (CGT), small molecule drug modification, and microbiome therapeutics.
Chairman Seo outlined future plans to develop a small-scale cGMP platform service, a critical step for advancing the CGT business. He noted, “We aim to complete a cGMP platform for cell and gene therapies within 2–3 years. We’re also expanding into mRNA vaccine development and peptide-related services, including obesity treatments.”
To strengthen global competitiveness, BioSolutions will establish research centers in the United States, Europe, and India, while maintaining its main research hub in Korea. Sales offices will be aligned with 파라오 슬롯’s more than 40 global subsidiaries.
The 파라오 슬롯 headquarters, located in Songdo, Incheon, will house a 200,000-liter production facility, with plans to consider an additional 100,000-liter facility for overseas expansion, depending on demand.
Chairman Seo forecasted revenue growth from CDO and CRO services, anticipating million by 2027 and 0 million by 2030. He emphasized high-value services to ensure a minimum revenue of million per 10,000 liters of production capacity.
He concluded, “We have initially invested million in 파라오 슬롯 and plan a total investment of .4 to 2.1 billion, utilizing internal funds and external financing if necessary.”